<p>圣地亚哥 --（商业资讯）--Gossamer Bio, Inc.（纳斯达克：GOSS）是一家处于后期阶段的临床生物制药公司，专注于 seralutinib 的开发和商业化，以治疗肺动脉高压（PAH）和与间质性肺病相关的肺高压（PH-ILD）。今天宣布，Gossamer 董事会的薪酬委员会批准了授予一名非执行员工的非合格股票期权奖励，生效日期为 2025 年 12 月 5 日，允许其购买最多 200,000 股公司普通股，依据 Gossamer Bio, Inc. 2023 年雇佣诱导激励奖励计划（“2023 诱导计划”）。该奖励是作为员工入职 Gossamer 的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>这些期权的行使价格为每股 3.33 美元，等于 2025 年 12 月 5 日 Gossamer 普通股在纳斯达克全球精选市场报告的收盘价。期权的有效期为十年，将在四年内逐步归属，其中 25% 将在适用归属开始日期的一周年纪念日归属，其余股份将在此后以 36 个连续的月度分期归属，前提是员工在这些归属日期继续在 Gossamer 工作。期权受 2023 诱导计划的条款和条件以及涵盖授予的股票期权协议的条款和条件的约束。</p>
<p><strong>关于 Gossamer Bio</strong></p>
<p>Gossamer Bio 是一家处于后期阶段的临床生物制药公司，专注于 seralutinib 的开发和商业化，以治疗肺动脉高压和与间质性肺病相关的肺高压。其目标是成为行业领导者，并改善肺高压患者的生活。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDk2MDY4MzJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDk2MDY4MzJyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251209606832/en/</p>
<p><strong>投资者和媒体联系：</strong></p>
<p>Bryan Giraudo，首席运营官兼首席财务官</p>
<p>Gossamer Bio 投资者关系</p>
<p>ir@gossamerbio.com</p>
<p>来源：Gossamer Bio, Inc.</p>

GOSS

<p>Gossamer Bio 宣布根据纳斯达克上市规则 5635(c)(4) 进行诱导性授予，生效日期为 2025 年 12 月 5 日。该授予包括 200,000 股的非合格股票期权，行权价为每股 3.33 美元，分四年归属。这是 2023 年诱导计划的一部分，旨在吸引新员工。Gossamer Bio 专注于开发用于治疗肺动脉高压的 seralutinib</p>

<p>SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective December 5th, 2025, to a non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 200,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The award was granted as an inducement material to the employee entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>圣地亚哥 --（商业资讯）--Gossamer Bio, Inc.（纳斯达克：GOSS）是一家处于后期阶段的临床生物制药公司，专注于 seralutinib 的开发和商业化，以治疗肺动脉高压（PAH）和与间质性肺病相关的肺高压（PH-ILD）。今天宣布，Gossamer 董事会的薪酬委员会批准了授予一名非执行员工的非合格股票期权奖励，生效日期为 2025 年 12 月 5 日，允许其购买最多 200,000 股公司普通股，依据 Gossamer Bio, Inc. 2023 年雇佣诱导激励奖励计划（“2023 诱导计划”）。该奖励是作为员工入职 Gossamer 的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The options have an exercise price of $3.33 per share, which is equal to the closing price of Gossamer’s common stock as reported by The Nasdaq Global Select Market on December 5th, 2025. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive monthly installments thereafter, subject to the employee’s continued employment with Gossamer on such vesting dates. The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.</p>
<div class="lb-trans"><p>这些期权的行使价格为每股 3.33 美元，等于 2025 年 12 月 5 日 Gossamer 普通股在纳斯达克全球精选市场报告的收盘价。期权的有效期为十年，将在四年内逐步归属，其中 25% 将在适用归属开始日期的一周年纪念日归属，其余股份将在此后以 36 个连续的月度分期归属，前提是员工在这些归属日期继续在 Gossamer 工作。期权受 2023 诱导计划的条款和条件以及涵盖授予的股票期权协议的条款和条件的约束。</p>
</div><p><strong>About Gossamer Bio</strong></p>
<div class="lb-trans"><p><strong>关于 Gossamer Bio</strong></p>
</div><p>Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.</p>
<div class="lb-trans"><p>Gossamer Bio 是一家处于后期阶段的临床生物制药公司，专注于 seralutinib 的开发和商业化，以治疗肺动脉高压和与间质性肺病相关的肺高压。其目标是成为行业领导者，并改善肺高压患者的生活。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDk2MDY4MzJyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251209606832r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251209606832/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251209606832/en/</p>
</div><p><strong>For Investors and Media:</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体联系：</strong></p>
</div><p>Bryan Giraudo, Chief Operating Officer and Chief Financial Officer</p>
<div class="lb-trans"><p>Bryan Giraudo，首席运营官兼首席财务官</p>
</div><p>Gossamer Bio Investor Relations</p>
<div class="lb-trans"><p>Gossamer Bio 投资者关系</p>
</div><p>ir@gossamerbio.com</p>
<div class="lb-trans"><p>ir@gossamerbio.com</p>
</div><p>Source: Gossamer Bio, Inc.</p>
<div class="lb-trans"><p>来源：Gossamer Bio, Inc.</p>
</div>

Gossamer Bio 宣布根据纳斯达克上市规则 5635(c)(4) 进行激励性授予 | GOSS 股票新闻